634 Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies
Elisa C. Toffoli(Amsterdam University Medical Centers), Abdolkarim Sheikhi(Dezful University of Medical Sciences), Jurriaan B. Tuynman(Amsterdam Neuroscience), Tanja D. de Gruijl(Dutch Cancer Society), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Lisa A. King(Leiden University Medical Center), Roeland Lameris(Amsterdam UMC Location Vrije Universiteit Amsterdam), Henk M.W. Verheul(Erasmus MC Cancer Institute)
Cited by 1
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Epidemic Profile of Shiga-Toxin–Producing<i>Escherichia coli</i>O104:H4 Outbreak in Germany
|New England Journal of Medicine|2011|1.1k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795